Core Viewpoint - The strategic partnership between Eli Lilly, a leading pharmaceutical company, and Nvidia, a top technology giant, marks a significant shift in the pharmaceutical industry, focusing on AI-driven drug development and manufacturing processes [1][14]. Group 1: Partnership Details - Eli Lilly and Nvidia will invest $1 billion over five years to establish a joint innovation lab in the San Francisco Bay Area [1]. - The lab will not only serve as a computing center but will also aim to completely restructure the drug development process using AI [2]. - The partnership will utilize Nvidia's latest AI chip architecture, Vera Rubin, which is designed for high-precision scientific calculations essential for drug development [2][3]. Group 2: Technological Integration - The collaboration will integrate hardware and software, with Nvidia's BioNeMo platform and Eli Lilly's TuneLab platform combining to enhance drug discovery [3][4]. - BioNeMo will function as a generative AI platform for biology, capable of generating new protein structures, while Eli Lilly will contribute its extensive historical experimental data [3][4]. - The partnership aims to address the data and model gap in AI healthcare, leveraging federated learning technology [4]. Group 3: Manufacturing Innovations - The collaboration extends to manufacturing, with plans to create a "digital twin" of Eli Lilly's production line using Nvidia's Omniverse platform [5]. - This digital twin will simulate production processes to optimize supply chain efficiency, potentially leading to significant revenue increases for high-demand products [5]. Group 4: Industry Context and Implications - Eli Lilly's decision to partner with Nvidia reflects a strategic move to overcome the challenges of traditional drug development, which is often time-consuming and costly [6][7]. - The partnership signifies a shift from a "Discovery" to a "Design" paradigm in drug development, allowing for targeted molecular design rather than random screening [7][8]. - The collaboration is expected to accelerate industry changes, prompting other major pharmaceutical companies to seek similar technological partnerships [16][18]. Group 5: Future Outlook - The partnership is seen as a potential turning point in AI-driven pharmaceutical development, creating a new model of collaboration between top pharmaceutical and technology companies [15][16]. - The competition in the pharmaceutical industry is likely to intensify as companies race to secure technological alliances, with AI becoming a critical component of drug development [19][20].

Core Insights - The discovery of a super-Earth, Kepler-725c, in the habitable zone of a sun-like star, Kepler-725, represents a significant breakthrough in the search for extraterrestrial life [1][3] - The research was led by the Yunnan Observatory of the Chinese Academy of Sciences and utilized Transit Timing Variation (TTV) technology [1][4] - The findings were published in the prestigious journal Nature Astronomy, highlighting the potential for discovering Earth-like planets [1] Group 1 - The super-Earth Kepler-725c has a mass approximately 10 times that of Earth and is located in the habitable zone, which is crucial for the existence of liquid water [1][3] - Kepler-725, the host star, is a G9V type, younger than the Sun at 1.6 billion years old, and exhibits more intense magnetic activity [3][4] - The orbital period of Kepler-725c is about 207.5 days, which is similar to Earth's orbital period, suggesting potential similarities in environmental conditions [3] Group 2 - The discovery opens new avenues for finding "Earth 2.0" in the habitable zones of sun-like stars, which is essential for understanding the origins of life [1][4] - The distance from Earth to Kepler-725c is approximately 160 million kilometers, which is a significant distance in astronomical terms [4]

我今天已经不发烧了，这次没有流鼻涕咳嗽等症状，就是肚子吃坏了，腹泻很严重，一天要上七八次洗手间，从固体拉到液体，搞得我现 在放p都不敢坐在凳子上，我怕什么你们肯定懂的。已经吃了蒙脱石散，还买了一打的外星人电解质水补充，总的来说不碍事了。 未来人类想要走出太阳系，这副碳基的皮囊就是最大的短板，怕冷、怕热、气压低了高了都不行，必须刚刚好，每天需要摄入水和食物， 还要排泄，必须保持一定量运动维持健康，否则容易生病（生理+心理），理论寿命不超过150岁，在宇宙尺度而言这太短暂了。 进化了几亿年也就这水平，其它星系的生命估计也好不到哪去。所以宇宙就是一个又一个独立的孤岛，或者说监狱，文明和文明之间谁也 遇不到谁。有人可能觉得，我的想象力不够丰富，别的星系的生命也许是我想象不到的形式呢？ 可能性很小。我们由碳基形成生命不是一个巧合，而是这个物理规则的宇宙下，碳的分子结构和稳定性决定了它就是最适合的生命分子， 其它可能性也有，比如硅基、氨基、铁基，也有可能形成生命，但对环境的要求很苛刻，很不稳定。从星际航行的角度而言，这些生命体 的适应性还不如碳基，所以更没戏。 我假想过其它星球的生命，外形可能千奇百怪，但底层分子大概率和 ...